Saudi insurers must offer an outpatient health product with no pre-approval from 1 November 2026. The Insurance Authority set the date and the complaint route, but left the price, network and claims rules to the insurers.

The obligation falls on the insurer, which must make the product available. Nothing in the release requires an employer to move its staff onto it. For a clinic, that means the directive changes nothing on 1 November by itself.

Volume shifts only as employer groups and individual policyholders pick the new product, which on our reading happens mostly at renewal. A target whose outpatient volume comes from a handful of large corporate schemes will see the effect scheme by scheme, and the seller can find out which schemes are moving before the buyer does.

Pre-approval in Saudi private insurance is already time-limited. The unified Cooperative Health Insurance Policy requires the insurer to respond to a provider's approval request within sixty minutes (Cooperative Health Insurance Policy).

The beneficiaries' rights regulation, code CCHI-08-BL-02-1/0, repeats the 60-minute limit in Article 8(10), requires reasons and standard denial codes on any refusal in Article 8(13), and deems a request approved if no answer arrives within 60 minutes in Article 8(14) (Health Insurance Beneficiaries Rights).

Article 4(7) states the same 60-minute limit as a right of the patient. Article 9(7) of the same regulation gives the provider 15 minutes to submit the request after the physician fills it in. So the directive removes a step that is already on a clock. What it removes is the insurer's right to say no before the service, and the administrative desk that runs the exchange.

The release sets a date and a complaint route. It says nothing about price, co-payment, deductible, network, annual limits or how outpatient claims under the new product will be checked. Those are the terms that decide what the product means for a provider, and the Authority has left them to the insurers. A buyer should not model the product from the headline. An outpatient benefit with no approval and a narrow network is a different revenue line for an excluded clinic than the same benefit on an open network.

An insurer that loses the approval step still has to price outpatient risk. On our reading it has four places to do that: a higher premium, a higher co-payment, a narrower network and closer review of claims after treatment. The first two fall on the employer and the patient.

The last two fall on the provider. A refused pre-approval costs a clinic a visit it did not deliver. A rejected claim costs it a visit it already delivered. For a target whose forecast assumes today's refusal rate simply disappears, that is the line to test.

Where the new product is priced on an open network, a clinic can expect more visits with less front-desk work. Where insurers use it to steer members to preferred providers, a clinic outside those networks loses volume it currently wins.

Either way, the effect arrives through contracts the target is negotiating now, in the weeks before 1 November, and none of it is in trailing accounts. The complaint route makes the shift harder to delay: from 1 November an employer that asks for the product and is refused can take it to the Authority.